About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in North Carolina | 15,496 Studies Near You | Clareo Health

Clinical Trials LocationsNorth Carolina

Clinical Trials in North Carolina

Discover 15,496 clinical trials near North Carolina. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 10081-10100 of 15,496 trials

COMPLETEDPhase 157 miles

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

NCT02960854

A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.

Bristol-Myers Squibb38 participantsStarted Dec 2016

Sacramento, California, United States • Colorado Springs, Colorado, United States • Denver, Colorado, United States +13 more locations

COMPLETED57 miles

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

NCT03208660

This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.

Eisai Inc.2,000 participantsStarted Apr 2017

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +41 more locations

Find Trials by Condition in North Carolina

Breast Cancerin North Carolina Lung Cancerin North Carolina Prostate Cancerin North Carolina Colorectal Cancerin North Carolina Melanomain North Carolina Leukemiain North Carolina Lymphomain North Carolina Pancreatic Cancerin North Carolina Ovarian Cancerin North Carolina Brain Cancerin North Carolina

Data from ClinicalTrials.govTerms

COMPLETEDPhase 257 miles

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

NCT01381874

The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in postmenopausal women with estrogen receptor-positive (ER+) metastatic (spreading) breast cancer that has relapsed after treatment with letrozole or anastrozole.

Metastatic ER+ Her2- Breast CancerPostmenopausal

Janssen Research & Development, LLC297 participantsStarted Aug 2011

Muscle Shoals, Alabama, United States • Fresno, California, United States • Los Angeles, California, United States +78 more locations

COMPLETEDNA143 miles

Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers

NCT02416076

Up to 40 participants will be enrolled, randomized and treated. Enrolled participants will receive one, split-face Ulthera® treatment on the face and neck using a Ulthera System standard transducer on one side of the face and a Ulthera System prototype simulines transducers on the other side of the face. Follow-up visits will occur at 90 and 180 days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.

Ulthera, Inc42 participantsStarted Dec 2014

Beverly Hills, California, United States • Saratoga, California, United States • Wilmington, North Carolina, United States

COMPLETEDNA181 miles

Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes

NCT02463097

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm that is built into the 670G insulin pump is safe as part of the overall system.

Type 1 Diabetes

Medtronic MiniMed, Inc.124 participantsStarted Jun 2015

Escondido, California, United States • Palo Alto, California, United States • Aurora, Colorado, United States +7 more locations

COMPLETEDPhase 3197 miles

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

NCT01211873

The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.

Diagnostic Self EvaluationCentral Nervous System Diseases

Guerbet416 participantsStarted Sep 2010

Birmingham, Alabama, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +49 more locations

COMPLETEDNA197 miles

Assessment of nanOss Bioactive 3D in the Posterolateral Spine

NCT01829997

Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive 3D can be mixed with bone marrow aspirate (BMA) and autograft bone to obtain new bone growth during the healing process. nanOss Bioactive 3D is approved for use in the U.S., however, additional information is useful to assess its efficacy in the posterolateral spine. The purpose of this study is to assess fusion results in the posterolateral spine using nanOss Bioactive 3D mixed with autograft bone and BMA. It is hypothesized that the use of nanOss Bioactive 3D will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion.

Degenerative Disc DiseaseSpinal StenosisSpondylolisthesis

Pioneer Surgical Technology, Inc.22 participantsStarted Apr 2013

New York, New York, United States • New York, New York, United States • Charleston, South Carolina, United States +1 more locations

TERMINATEDPhase 1/2197 miles

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

NCT02568683

The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.

Non-Hodgkin Lymphoma

Gilead Sciences10 participantsStarted Feb 2016

Hattiesburg, Mississippi, United States • Charleston, South Carolina, United States • Pessac, Aquitaine, France +4 more locations

COMPLETEDPhase 1275 miles

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

NCT02408913

Background: \- Ebola virus is a rare disease that starts with fever and muscle aches, but can lead to death. The 2014 Ebola outbreak in West Africa is the largest to date. There are no approved treatments for Ebola. Researchers want to see if two new vaccines VRC-EBOMVA079-00-VP (MVA-EbolaZ) and VRC-EBOADC069-00VP ( cAd3-EBO ) are safe and able to induce an immune response against Ebola. Objectives: \- To see if the two new vaccines are safe and if they cause any side effects. Also, to study immune responses to the vaccines. Eligibility: \- Healthy adults ages 18-66 Design: * Participants will get one or two study vaccine injections depending on the study group they are assigned to. Each injection will repeat the same schedule: * A needle and syringe will inject the vaccine into an upper arm muscle. * 1-2 days later, participants must call the clinic to report how they feel. * For 7 days they will check their temperature with a thermometer given to them. They will look at the injection site, and measure any redness or swelling with a ruler. They will write down any symptoms they have. * In the first 2 months, participants will have at least 6 clinic visits and 1 phone contact. At each visit, participants will be checked for health changes or problems. They will tell how they feel and if they have taken any medications. Blood and urine samples may be collected. * Participants might need to have extra clinic visits and laboratory tests if they have health changes that need to be checked.

Healthy Adult Immune Responses to Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)140 participantsStarted Mar 2015

Decatur, Georgia, United States • Baltimore, Maryland, United States • Bethesda, Maryland, United States

TERMINATEDPhase 2291 miles

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT03185481

The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Parkinson's Disease With Motor Fluctuations

Pfizer5 participantsStarted Jul 2017

Newport Beach, California, United States • Fairfield, Connecticut, United States • Boca Raton, Florida, United States +6 more locations

COMPLETEDPhase 3340 miles

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

NCT01989468

The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis factor alpha (TNFα) therapy.

Psoriatic Arthritis

Novartis Pharmaceuticals414 participantsStarted Apr 2014

Aventura, Florida, United States • Palm Harbor, Florida, United States • Sarasota, Florida, United States +74 more locations

COMPLETED354 miles

Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC

NCT01767779

To determine whether EEGs during infancy is a reliable biomarker to identify TSC patients that will develop infantile spasms/epilepsy in the near future and thus are appropriate candidates for an antiepileptogenic drug trial. Since not all patients with TSC develop epilepsy, it would be useful to have a biomarker that could predict those patients destined to have epilepsy and thus identify those TSC patients most appropriate for an antiepileptogenic drug trial. A recent study suggests that treating TSC patients with an abnormal EEG prior to onset of infantile spasms with vigabatrin may improve neurological outcome, but the use of EEG as a reliable biomarker of future epilepsy has not been rigorously validated. In this specific aim, we will test the reliability of EEG in predicting future development of infantile spasms or epilepsy in TSC patients during the first year of life.

Tuberous Sclerosis Complex

University of Alabama at Birmingham40 participantsStarted Sep 2012

Birmingham, Alabama, United States • Los Angeles, California, United States • Boston, Massachusetts, United States +2 more locations

COMPLETED518 miles

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

NCT01608672

This is an observational study assessing patient satisfaction following at least 5 years of BOTOX® treatment for glabellar lines.

Glabellar Lines

Allergan207 participantsStarted Apr 2012

Coral Gables, Florida, United States • South Yarra, Australia • São Paulo, Brazil +2 more locations

COMPLETEDPhase 3549 miles

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168298

This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of macular edema associated with retinal vein occlusion.

Macular EdemaRetinal Vein Occlusion

Allergan668 participantsStarted Nov 2004

Houston, Texas, United States • São Paulo, Brazil • Mississauga, Ontario, Canada +10 more locations

COMPLETEDPhase 3558 miles

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519

A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with overactive bladder (OAB) and urinary incontinence.

Overactive BladderUrinary Incontinence

Allergan356 participantsStarted Mar 2013

Newport Beach, California, United States • Leuven, Belgium • Vancouver, British Columbia, Canada +5 more locations

COMPLETEDPhase 2569 miles

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02083653

This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).

Metastatic Colorectal Cancer

Symphogen A/S254 participantsStarted Mar 2014

Los Angeles, California, United States • San Diego, California, United States • Fort Myers, Florida, United States +51 more locations

COMPLETEDNA572 miles

A Randomized Trial of Effects of Parent Mentors on Insuring Minority Children

NCT01264718

The Kids' HELP trial rigorously documented that a Parent Mentor intervention results in multiple benefits: more children are insured faster, children's access to healthcare and parental satisfaction improve, quality of well-child care is enhanced, thousands of dollars are saved per child, jobs are created, disparities are eliminated, and the intervention potentially could save our nation billions of dollars.

Uninsured Children Eligible for Medicaid or CHIP

University of Texas Southwestern Medical Center329 participantsStarted Dec 2010

Hartford, Connecticut, United States • Dallas, Texas, United States

COMPLETEDPhase 3669 miles

Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

NCT03427151

this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main study IP-005.

Lupus Erythematosus, Systemic

ImmuPharma62 participantsStarted Feb 2018

Los Angeles, California, United States • San Leandro, California, United States • Aventura, Florida, United States +11 more locations

COMPLETEDPhase 21008 miles

Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

NCT01492400

This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).

Allergan363 participantsStarted Mar 2012

Arlington, Texas, United States • Brussels, Belgium • Copenhagen, Denmark +10 more locations

COMPLETEDPhase 21835 miles

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

NCT01397409

This study is conducted in 3 stages. Stage 1 is an open-label, dose-escalation assessment of the safety of AGN-150998 administered as a single intravitreal injection to patients with advanced exudative Age-related Macular Degeneration (AMD). Stage 2 and Stage 3 are randomized, double-masked, comparisons of the safety and treatment effects on retinal edema and best-corrected visual acuity (BCVA) of AGN-150998 and ranibizumab in treatment-naive patients with exudative AMD. Study medication is administered as needed in Stage 2 and with a fixed-dosing schedule in Stage 3. The study objectives are (1) to identify the highest tolerated dose of AGN-150998, (2) to assess the safety and duration of treatment effects on retinal edema and BCVA, and (3) to characterize the systemic pharmacokinetic profile of AGN-150998.

Age-related Macular Degeneration

Allergan271 participantsStarted Sep 2011

Phoenix, Arizona, United States • Sydney, New South Wales, Australia • Vienna, Austria +5 more locations

PreviousPage 505 of 775Next

Diabetes

in North Carolina

Heart Diseasein North Carolina